Evidence map›Paper›PMID 37193227›Full record

ArticleBiofilm2023

Antifungal therapy of

Olabayo H Ajetunmobi, Hamid Badali, Jesus A Romo, Gordon Ramage, Jose L Lopez-Ribot

Open access · goldAbstract read
In one paragraph

Article in Biofilm, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Morphotype-specific susceptibility toMicrobiology spectrum · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Safety and efficacy of echinocandin antifungal agents inAntimicrobial agents and chemotherapy · 2026
    Article
  10. Article
  11. Review
  12. The roles ofFrontiers in medicine · 2026
    Article
  13. Article
  14. Bioactive Constituents ofDrug design, development and therapy · 2026
    Review
  15. Article
  16. Review
  17. Article
  18. Chitosan nanoparticles encapsulating farnesol show potent antifungal activity against Candida albicans biofilms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  19. Myricetin Exerts Antibiofilm Effects onJournal of fungi (Basel, Switzerland) · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Olabayo H AjetunmobiDepartment of Molecular Microbiology & Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX, USA.
Hamid BadaliDepartment of Molecular Microbiology & Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX, USA.
Jesus A RomoDepartment of Molecular Microbiology & Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX, USA.
Gordon RamageGlasgow Biofilm Research Network, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8TA, UK.
Jose L Lopez-RibotDepartment of Molecular Microbiology & Immunology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX, USA.
Texas Center for Infectious Disease · USUniversity of Glasgow · GB

Funding

UTSA RISE Research Training ProgramR25GM060655 · NIGMS · UNIVERSITY OF TEXAS SAN ANTONIO · PI BAREA-RODRIGUEZ, EDWIN J · 2000 to 2022
$21.6M
NIGMS NIH HHS R25 GM060655
6 · The paper itself

Abstract

Virtually all

Indexed as

Antifungal agentsBiofilmCandida spp.

Identifiers

PMID37193227
PMCPMC10182175
OpenAlexW4366779695

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.